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Abstract
Purpose Low 25-hydroxyvitamin D (25[OH]D) concentrations have been associated with adverse outcomes in selected 
populations with established chronic heart failure (CHF). However, it remains unclear whether 25[OH]D deficiency is associ-
ated with mortality and hospitalisation in unselected patients receiving contemporary medical and device therapy for CHF.
Methods We prospectively examined the prevalence and correlates of 25[OH]D deficiency in 1802 ambulatory patients 
with CHF due to left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 45%) attending heart failure clinics 
in the north of England.
Results 73% of patients were deficient in 25[OH]D (< 50 nmol/L). 25[OH]D deficiency was associated with male sex, diabe-
tes, lower serum sodium, higher heart rate, and greater diuretic requirement. During a mean follow-up period of 4 years, each 
2.72-fold increment in 25[OH]D concentration (for example from 32 to 87 nmol/L) is associated with 14% lower all-cause 
mortality (95% confidence interval (CI) 1, 26%; p = 0.04), after accounting for potential confounding factors.
Conclusions Low 25-hydroxyvitamin D deficiency is associated with increased mortality in patients with chronic heart failure 
due to left ventricular systolic dysfunction. Whether vitamin D supplementation will improve outcomes is, as yet, unproven.
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Abbreviations
CHF  Chronic heart failure
LV  Left ventricular
LVEF  Left ventricular ejection fraction
eGFR  Estimated glomerular filtration rate
NYHA  New York Heart Association
ACEi  Angiotensin-converting enzyme 
inhibitor
ARB  Angiotensin receptor blocker
ONS  Office of National Statistics
CI  Confidence interval
HR  Hazard ratio
VINDICATE study  Vitamin D treating patients with 
chronic heart failure
EVITA study  Effect of Vitamin D on all-cause 
mortality in heart failure study
VIDA study  Vitamin D assessment study
IQR  Interquartile range
PTH  Parathyroid hormone
Introduction
Vitamin D is receiving increasing attention as epidemio-
logical evidence links it to many chronic illnesses. Low 
serum 25-hydroxyvitamin D (25[OH]D) concentrations 
have been associated with an increased risk of adverse 
outcomes generally, [1, 2] but especially in patients with 
suspected coronary artery disease, hypertension and 
chronic heart failure (CHF) [3–10]. However, published 
data pertaining to CHF are derived from registry data, or 
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somewhat selected cohorts such as patients referred for 
coronary angiography, on a waiting list for cardiac trans-
plantation or in-patients. Vitamin D has multiple effects 
throughout the body that may be of particular relevance 
in people with CHF [11]. We have recently described in a 
randomised, placebo-controlled trial in unselected ambu-
latory patients with CHF and 25[OH]D deficiency that 
vitamin  D3 supplementation (100 mcg (4000 IU) daily) 
improves left ventricular structure and function [12]. 
Whether 25[OH]D deficiency independently predicts out-
comes in unselected patients with CHF remains unclear.
In a prospective cohort study, we examined the preva-
lence and correlates of 25[OH]D deficiency and whether 
25[OH]D levels were related to hospitalisation and mortal-
ity outcomes in unselected patients referred to heart failure 
clinics in the north of England.
Methods
As described in our previous publications [13, 14], adult 
patients (> 18  years) were eligible to take part in the 
cohort study if they had stable symptoms and signs of CHF 
for 3 months, in addition to echocardiographic evidence of 
left ventricular systolic dysfunction (left ventricular (LV) 
ejection fraction (LVEF) ≤ 45%). Between June 2006 and 
July 2014, we recruited patients from the outpatient heart 
failure clinics of four hospitals in the north of England. 
Ethical approval was provided by Leeds West Research 
Ethics Committee (07/Q1205/17), and all patients pro-
vided written informed consent to participate.
Baseline assessment
All patients underwent resting 12-lead electrocardio-
graphs, and blood testing for measurement of full blood 
count, electrolytes, serum creatinine and serum 25(OH)D2 
and 25(OH)D3 concentration. Estimated glomerular filtra-
tion rate (eGFR) was calculated using the Modification of 
Diet in Renal Disease method [15]. Functional status was 
assessed using the New York Heart Association (NYHA) 
classification. Two-dimensional transthoracic echocardi-
ography was performed in all participants by sonographers 
blinded to patient characteristics; left ventricular (LV) 
ejection fraction (LVEF) was calculated according to the 
Simpson’s biplane method. Doses of diuretic therapy, 
angiotensin-converting enzyme inhibitors (ACEi), angio-
tensin receptor blockers (ARB), and beta-blockers were 
normalised to maximum licensed CHF dose as previously 
described [10].
25[OH]D concentration
Serum 25(OH)D2 and 25(OH)D3 concentrations were 
analysed by tandem mass spectrometry. Samples were 
prepared using a protein precipitation reagent containing 
deuterated 25(OH)D3. The supernatant was analysed on 
an API5000 LC-MS/MS (AB SCIEX, Warrington, UK) 
in APCI mode. The inter-assay CV was < 10% at all con-
centrations ranging from 12 to 159 nmol/L. 25(OH)D2 and 
 D3 concentrations were summed and reported as 25(OH)D. 
We defined deficiency of 25[OH]D concentrations based 
upon the threshold outlined by the Endocrine Society call-
ing 25[OH]D < 50 nmol/L deficient [16].
Hospitalisation and mortality
The nature and duration of non-elective hospitalisation 
within the first year after enrolment was determined using 
hospital databases. Each hospitalisation was sub-classified 
independently by two cardiologists as cardiovascular if 
the principal presenting complaint was related to cardiac, 
cerebrovascular or peripheral vascular disease; consensus 
was sought in all initial cases of disagreement. Cardio-
vascular admissions were further sub-classified as heart 
failure related if the patient presented with symptoms 
and signs of heart failure and evidence of fluid overload 
requiring intravenous diuretic therapy for at least 24 h. All 
patients were registered with the United Kingdom Office 
of National Statistics (ONS) to provide details of death 
until the censoring date of 8th May 2016.
Statistical methods
Analyses were conducted in Stata (StataCorp. 2015. Stata 
Statistical Software: Release 14. College Station, TX). All 
significance tests were two sided and called significant 
at the 5% level. Continuous data are expressed as mean 
(SEM) or median (IQR) depending on normality of distri-
bution, and categorical variables as n (%).
Odds ratios (binary logistic regression) and hazard 
ratios (Cox proportional hazards regression) were derived 
for the association between 25[OH]D and hospitalisation 
or mortality, respectively. 25[OH]D concentrations were 
natural log transformed during these analyses to account 
for their non-normal distribution. After defining crude 
(unadjusted) associations, models were used to adjust for 
patient and clinical demographics (age, sex, month and 
year of recruitment, sodium, eGFR, albumin, log trans-
formed QRS interval, NYHA class, LVEF, LV end dias-
tolic dimension), comorbidities and aetiology (diabetes 
European Journal of Nutrition 
1 3
mellitus, chronic obstructive pulmonary disease (COPD), 
ischaemic aetiology) and treatment (ramipril dose, biso-
prolol dose, furosemide dose and device therapy).
Multiple imputation by chained equations, under the 
missing at random assumption, was used to impute 30 sets 
of data to minimise any potential bias caused by missing 
data (see Table 1) [17, 18]. The imputation model speci-
fication was such that it included all variables included in 
the analysis model, including outcome variables (hospi-
talisation, Nelson–Aalen survival estimator and censoring 
indicator [19]), as well as auxiliary variables as indicated 
in supplementary table 1, following previously defined 
methods [20]. Results presented in the manuscript contain 
estimates averaged over 30 imputed data sets, according to 
Rubin’s rules, and were compared to complete case analy-
ses (i.e. without imputation), presented in supplementary 
tables 2 and 3, to check for consistency.
Results
A total of 1802 patients were recruited to the study [mean 
(SEM) age 69.6 (0.3) and 1319 (73.2%) male]. Median (IQR) 
25[OH]D concentration within the 1252 patients with availa-
ble data was 32.1 (20–52) nmol/L. Few patients (9.1%) were 
sufficient in 25[OH]D (≥ 75 nmol/L) at baseline (Fig. 1), and 
914 (73%) were deficient (< 50 nmol/L). Although 25[OH]
D concentrations varied throughout the year (Fig. 2), even 
during months with greater daylight, median concentrations 
remained in the deficiency range (April–September − 35.4 
(21.9–56) nmol/L, and October–March − 30 (19.9–48) 
nmol/L; p = 0.001 by Mann–Whitney test).
Patients deficient in 25[OH]D were more likely to be 
male, and have diabetes, whilst the distribution of heart fail-
ure aetiology was not different between the groups (Table 1). 
Deficient patients also had higher heart rates, lower serum 
sodium levels, and a greater furosemide requirement. 
Table 1  Variables according to 25[OH]D concentration (≥/<50 nmol/l)
Continuous data all as mean (SD), categorical data are n, %
eGFR estimated glomerular filtration rate, LV left ventricular, COPD chronic obstructive pulmonary disease, NYHA New York Heart Associa-
tion Class
Whole cohort 25[OH]D < 50 25[OH]D ≥ 50 p value Missing
n = 1802 n = 914 n = 338 25[OH]D groups n (%)
Age (years) 69.6 (12.5) 69.9 (12.7) 71.2 (11.2) 0.07 0 (0)
Heart rate (bpm) 75.3 (17.9) 76.4 (18.3) 73.6 (17.2) 0.017 158 (8.8)
QRS interval (ms) 123.2 (31) 123.8 (31.4) 123.7 (31.4) 0.94 157 (8.7)
Haemoglobin (g/dl) 13.5 (1.8) 13.5 (1.8) 13.4 (1.8) 0.35 20 (1.1)
Sodium (mmol/L) 139.4 (3.4) 139.2 (3.5) 139.9 (3) 0.001 4 (0.2)
eGFR (ml/kg/1.73 m2) 57.8 (19.7) 58.5 (19.5) 57.3 (20.7) 0.36 8 (0.4)
Albumin (g/l) 43.1 (11.1) 42.8 (3.7) 43.1 (3.8) 0.29 56 (3.1)
LV end diastolic dimension (mm) 57.2 (8.9) 57 (8.6) 56.7 (8.9) 0.53 71 (3.9)
LV ejection fraction (%) 32 (9.5) 31.6 (9.3) 32.2 (9.4) 0.26 45 (2.5)
Ramipril dose (mg/day) 4.9 (3.5) 4.8 (3.6) 5 (3.5) 0.37 5 (0.3)
Bisoprolol dose (mg/day) 3.9 (3.4) 4 (3.4) 4 (3.3) 0.89 5 (0.3)
Prescribed ACEi/ARB (n, %) 1626 (90.4) 818 (89.7) 309 (91.4) 0.36 5 (0.3)
Prescribed beta-blocker (n, %) 1523 (84.7) 782 (85.7) 289 (85.5) 0.91 5 (0.3)
Prescribed mineralocorticoid receptor 
antagonist (n, %)
689 (38.2) 367 (40.2) 111 (32.8) 0.017 5 (0.3)
Furosemide (mg/day) 51.2 (1.2) 54.4 (1.6) 44.1 (2.6) 0.001 5 (0.3)
Male sex (n, %) 1319 (73.2) 678 (74.2) 230 (68) 0.031 0 (0)
Ischaemic aetiology (n, %) 1067 (59.2) 544 (59.5) 187 (55.3) 0.18 0 (0)
Diabetes (n, %) 504 (28) 287 (31.4) 77 (22.8) 0.003 0 (0)
COPD (n, %) 284 (15.8) 144 (15.8) 52 (15.4) 0.87 0 (0)
Device therapy (n, %) 504 (28) 247 (27) 109 (32.2) 0.07 0 (0)
NYHA class 1 (n, %) 333 (18.5) 132 (14.4) 66 (19.5) 0.05 2 (0.1)
 2 912 (50.7) 478 (52.3) 179 (53)
 3 534 (29.7) 294 (32.2) 92 (27.2)
 4 21 (1.2) 10 (1.1) 1 (0.3)
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Median 25[OH]D concentrations were significantly related 
to symptoms: 36.4 (22–57), 33.0 (21–52), 28.5 (19.8–48) 
and 18.4 (10–42)nmol/L for NYHA classes I–IV, respec-
tively, (p = 0.0005 by Kruskal–Wallis test).
Hospitalisation and mortality outcomes
Using routine data collection, we had 100% follow-up. 
Table 2 describes the association of natural log-transformed 
25[OH]D concentration with hospitalisation during the first 
year of follow-up, both before and after adjustment for 
potential confounding factors. Although 25[OH]D concen-
trations were associated with heart failure-specific, cardio-
vascular and all-cause hospitalisation in unadjusted analyses, 
there was no association in all cases after accounting for 
potential confounding factors. The same conclusions were 
reached when analyses were repeated without multiple 
imputation (supplementary table 2).
The association between natural log-transformed 25[OH]
D and mortality was significant in all of the unadjusted and 
adjusted analyses (Table 3) with a 19% lower mortality in 
non-deficient patients. These analyses suggest that even after 
accounting for all other variables described in Table 1, a 
2.72-fold increase in 25[OH]D (for example, an increase of 
25[OH]D from 32 to 87 nmol/L) is associated with a 14% 
lower risk of death. Broadly similar effect size and statisti-
cal significance were noted when repeating analyses with-
out multiple imputation (supplementary table 3). Adjusted 
survival curves with 95% confidence intervals for 25[OH]
D deficient and non-deficient patients are shown in Fig. 3, 
again revealing significantly higher mortality in deficient 
patients (HR 1.24, 95% CI 1.05, 1.46).
Discussion
Our data from a large prospectively collected cohort of unse-
lected ambulatory patients with CHF suggest that 25[OH]
D deficiency (25[OH]D < 50 nmol/L) is highly prevalent, 
persists during summer and autumn, and is an independent 
predictor of increased mortality. After adjusting for multi-
ple confounders, the outcome data from the cohort study 
are consistent with previous smaller reports in ambulatory 
patients [9, 21, 22], hospitalised patients [10] and registry 
data [3, 6, 23], and reveal increased mortality in patients 
with low 25[OH]D concentrations compared with those 
without. In all of these previous studies, 25[OH]D deficiency 
was less frequent than in our cohort ranging from 28 to 75% 
[10, 24], whilst overall mortality of the cohorts was higher. 
Our cohort study was prospectively designed to assess pre-
dictors of outcome in an unselected, consecutive group of 
patients with heart failure due to left ventricular systolic 
dysfunction on optimal contemporary medical and device 
therapy, and provides the strongest evidence to date that a 
low 25[OH]D concentration is an independent predictor of 
mortality.
Why might vitamin D be important in chronic heart 
failure?
Clinical evidence linking micronutrients and cardiovascular 
disease overall remains neutral [24]. Vitamin D, on the other 
hand, has multiple effects on the cardiovascular system [25] 
Fig. 1  25[OH]D concentrations in patients with chronic heart failure. 
Distribution of 25(OH)D concentrations in 1252 patients, indicating 
deficiency (< 50 nmol/L) in 73%
Fig. 2  25[OH]D concentrations in patients with chronic heart failure. 
Monthly variation of 25[OH]D concentration (median and interquar-
tile range) in 1252 patients. Boxes represent median and interquartile 
range (IQR), with whiskers denoting 1.5 ×  IQR and circles outliers 
beyond this range
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that might be especially pertinent to the heart failure syn-
drome [9, 26, 27].
Abnormalities of the vitamin D–parathyroid (PTH) axis 
have a direct effect upon a wide range of mammalian cells 
including cardiomyocytes. Through increased urinary excre-
tion of calcium and magnesium, enhanced by loop diuretic 
use [28, 29], elevated aldosterone levels drive PTH release. 
This response is exacerbated in people with 25[OH]D defi-
ciency [30, 31]. The consequences of 25[OH]D deficiency 
[32] and elevated PTH levels [33–36] are calcium loading, 
with cardiomyocyte and skeletal muscle contractile dys-
function, cellular hypertrophy, oxidative stress, immune 
activation, endothelial dysfunction (including enhanced 
endothelin-1 release) [30, 34, 37–41]. These influences are 
reflected clinically with an increased risk of hospitalisation 
[7, 42], and worsening renal function [43], whilst vitamin 
D supplementation may be associated with a reduction of 
plasma renin and aldosterone levels [44, 45]. Consistent with 
Table 2  Association of 25[OH]D with hospitalisation at 1 year (logistic regression analysis) after multiple imputation
Multiple imputation by chained equations was performed with 30 imputations and 20 iterations, and all model estimates are averaged over all 
imputed datasets
** OR per 2.72-fold increase in 25[OH]D (due to natural log transformation to achieve normality)
a Including age, sex, month and year of recruitment, sodium, eGFR, albumin, log-transformed QRS interval, NYHA class, LV ejection fraction, 
LV end diastolic dimension
b Diabetes, COPD, ischaemic aetiology
c Ramipril dose, bisoprolol dose, furosemide dose, and device therapy
Model OR** Lower 95% CI Upper 95% CI p value
Heart failure hospitalisation (n = 112, 6.2%)
 Unadjusted 0.67 0.46 0.97 0.034
 Adjusted for patient and clinical  demographicsa 0.76 0.52 1.12 0.165
 Adjusted for patient and clinical demographics, and comorbidities and  aetiologyb 0.79 0.54 1.16 0.223
 Adjusted for patient and clinical demographics, comorbidities and aetiology, and  treatmentc 0.80 0.54 1.19 0.270
Cardiovascular hospitalisation (n = 227, 12.6%)
 Unadjusted 0.78 0.59 1.01 0.061
 Adjusted for patient and clinical  demographicsa 0.84 0.64 1.10 0.202
 Adjusted for patient and clinical demographics, and comorbidities and  aetiologyb 0.86 0.65 1.13 0.280
 Adjusted for patient and clinical demographics, comorbidities and aetiology, and  treatmentc 0.87 0.66 1.15 0.330
All non-elective hospitalisations (457, 25.4%)
 Unadjusted 0.78 0.64 0.95 0.011
 Adjusted for patient and clinical  demographicsa 0.84 0.68 1.03 0.086
 Adjusted for patient and clinical demographics, and comorbidities and  aetiologyb 0.85 0.69 1.04 0.111
 Adjusted for patient and clinical demographics, comorbidities and aetiology, and  treatmentc 0.86 0.70 1.05 0.139
Table 3  Association of 25[OH]
D with all-cause mortality 
using Cox proportional hazards 
modelling after multiple 
imputation
Multiple imputation by chained equations was performed with 30 imputations and 20 iterations, and all 
model estimates are averaged over all imputed datasets
a HR per 2.72-fold increase in 25[OH]D (due to natural log transformation to achieve normality)
b Including age, sex, month and year of recruitment, sodium, eGFR, albumin, log-transformed QRS inter-
val, NYHA class, LV ejection fraction, LV end diastolic dimension
c Diabetes, COPD, Ischaemic aetiology
d Ramipril dose, bisoprolol dose, furosemide dose, and device therapy
Model HRa Lower 95% CI Upper 95% CI p value
All-cause mortality (n = 737, 40.9%)
 Unadjusted 0.79 0.69 0.91 0.001
 Adjusted for patient and clinical  demographicsb 0.83 0.72 0.96 0.011
 Adjusted for patient and clinical demographics, 
and comorbidities and  aetiologyc
0.84 0.72 0.97 0.016
 Adjusted for patient and clinical demographics, 
comorbidities and aetiology, and  treatmentd
0.86 0.74 0.99 0.042
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these observations, we found lower mean sodium levels and 
higher mean heart rates in 25[OH]D-deficient heart failure 
patients. Hence, the beneficial remodelling seen in VINDI-
CATE [9], and the adverse effects of 25[OH]D deficiency on 
outcomes demonstrated in the present report might reflect 
the interaction of vitamin D with several of the contribu-
tory pathophysiological pathways specific to CHF due to 
left ventricular systolic dysfunction.
Vitamin D as an intervention
A recent Cochrane review of 56 randomised trials with 
~ 95 K participants (> 99% healthy volunteers) showed that 
vitamin  D3 (given for mean 4.4 years) decreased all-cause 
mortality (RR 0.94, 95% CI 0.91–0.98). Vitamin  D2 had no 
effect. The authors called for more research in non-healthy 
populations [46]. A further systematic review and meta-anal-
ysis of observational and interventional studies suggested 
that vitamin  D3 supplementation might reduce mortality 
[47], with particular benefit in CHF patients. A subsequent 
trial analysis, systematic review and meta-analysis suggest 
that vitamin D supplementation might protect against fatal 
and non-fatal CHFs in older, healthy people (HR 0.75, 95% 
CI 0.58–0.97), but not against MI or stroke [48]. The most 
recent meta-analysis on non-skeletal effects of vitamin D 
supplementation demonstrates that most trials have been 
done in subjects without low 25[OH]D levels limiting the 
credibility of the argument that vitamin D supplementation 
has no potential benefit on outcomes in people with 25[OH]
D insufficiency [1].
The Vitamin D Assessment study (ViDA) in 5100 healthy 
subjects, aged > 50 years, recently reported that 100,000 IU 
oral vitamin  D3 monthly was neutral for the prevention of 
CV disease [49, 50], with a low rate of 25[OH]D deficiency 
in participants (25%), a lower than expected endpoint rate 
and monthly doses cited as possible reasons [51]. Meta-
analysis and data from ViDA and other studies describe 
that benefits on clinical outcomes are greatest in the most 
deficient, and in studies using daily dosing regimens (as in 
VINDICATE) rather than monthly [52–55].
Early trials of vitamin D supplementation in CHF were 
inconclusive possibly due to inclusion criteria, calcium-
based placebo, dosing regimen, use of vitamin  D2 (rather 
than  D3) and heterogeneous CHF population [56–58], limit-
ing their ability to provide clarity of benefit [25], whilst no 
trials have shown any adverse safety signals including up to 
10,000 IU daily [59]. Recent meta-analyses have suggested 
that vitamin D might reduce inflammation (assessed by 
tumour necrosis factor-alpha levels (TNF-α) [60]), but that 
it is neutral for heart function [61]. However, the latter analy-
sis did not include data from the VINDICATE paper which 
presented data from two independent randomised, placebo-
controlled, double-blind, parallel group studies using two 
imaging modalities demonstrating consistent improvements 
in left ventricular structure and function [9].
The single-centre ‘Effect of Vitamin D on all-cause mor-
tality in heart failure’ (EVITA) study is the only study of 
patient-orientated outcomes in CHF that has been reported. 
EVITA was neutral for mortality and heart failure hospi-
talisation [62]. EVITA recruited only 400 of an intended 
950 subjects (which would have given 80% power to detect 
a 36% reduction in total mortality) and had a drop-out rate 
of 42% at 3 years. Moreover, the median age of participants 
was 54yrs, with an unusually high (80%) device therapy rate, 
the study included people who were sufficient in 25[OH]
D (concentrations 50–75 mmol/L) and the group assigned 
vitamin D supplementation had significantly worse renal 
function and was 2 years older. In contrast, participants in 
our two studies and the present cohort study were ambu-
lant outpatients, mean age 70 years with a more typical 
device therapy rate (30%) and all had 25[OH]D concentra-
tions < 50 nmol/L [12].
Limitations
Although the results from our cohort study are significant 
despite the inclusion of numerous potential confounders 
in the models presented, our cohort outcome data remain 
observational. We accept, therefore, that it is possible that 
we have not accounted for all relevant confounding variables 
including, for example, social background and lifestyle that 
are difficult to measure. For example, the main source of 
vitamin D is not nutritional [63], rather the result of skin 
sunlight exposure. Hence, patients with chronic disease, 
Fig. 3  Adjusted survival according to 25[OH]D status. Adjusted sur-
vival curves according to 25[OH]D status (deficient and adequate) 
after multiple imputation, showing that after accounting patient and 
clinical demographics, comorbidities and aetiology, and treatment 
factors, 25[OH]D deficiency is associated with decreased survival 
(HR 1.24, 95% CI 1.05–1.46)
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immobility and the elderly (who require more sun exposure 
to make the same amount of vitamin D as younger indi-
viduals) are at higher risk of 25[OH]D deficiency since they 
spend less time outdoors [64]. 25[OH]D deficiency could, 
therefore, merely be a bystander, a marker of chronic disease 
or frailty, the result of limited sun exposure. This is, how-
ever, a limitation of all of the studies carried out so far and is 
countered by VINDICATE in which we observed important 
beneficial left ventricular remodelling with 12 months of 
vitamin D supplementation [9].
A potential limitation of our study is that although the 
blood of 25[OH]D vitamin D across centres was assessed 
using an accepted and validated process, we did not stand-
ardise samples across centres. However, decisions on inter-
vention in the form of vitamin D supplementation for CHF 
patients would be based upon results from local or regional 
services, abrogating the relevance of this limitation some-
what in real-world practice.
The headline results from the cohort study include data 
achieved through a robust and recognised multiple imputa-
tion process, which aims to reduce the bias introduced by 
excluding patients with missing 25[OH]D data. The results 
of the complete case analysis (i.e. without using multiple 
imputation) are presented in the supplementary materials 
and describe similar hazard ratios for mortality to those 
derived from analyses using multiple imputation.
Conclusion
Even after accounting for potential confounding factors, 
CHF patients with 25[OH]D sufficiency have a lower risk 
of all-cause mortality. In conjunction with our recent finding 
that vitamin D supplementation leads to beneficial cardiac 
remodelling, these data support the need for a longer term, 
fully recruited, randomised placebo-controlled study, with 
‘hard’ clinical endpoints, of high-dose vitamin  D3 supple-
mentation in patients with CHF due to left ventricular sys-
tolic dysfunction.
Clinical perspectives
25[OH]D deficiency (< 50 nmol/L) is common in patients 
with chronic heart failure and persists throughout the year. 
25[OH]D deficiency is an independent predictor of higher 
mortality in patients with CHF on optimal medical and 
device therapy.
Implications
Based upon these data and our previous work demonstrating 
improvements in cardiac function, it is possible that vitamin 
 D3 supplementation could improve outcomes in patients 
with heart failure due to left ventricular systolic dysfunction.
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